标题: 疫苗学《Vaccines》——6th Edition by (美)普洛特金 [打印本页] 作者: rojjer 时间: 2015-7-25 14:07 标题: 疫苗学《Vaccines》——6th Edition by (美)普洛特金
: v9 Q2 H* F; B7 {( t: v, ?2 [% W5 u
Vaccines, 6th Edition
( ?9 i" o& x1 x: Z
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice. ! Q' N0 N5 S( B; c . w( @: p& ^6 f0 [1 \/ B! Dhttp://yun.baidu.com/share/link?shareid=2079860221&uk=38109966061 e/ p- X, _' d& W" n* l
* y$ t, k7 ^1 \SECTION 1: General aspects of vaccination& I: i+ h' A# `" D% P
1 A short history of vaccination 1, I7 P% U1 X% H$ M+ Z
2 Vaccine immunology 14) [- `' V- ?- X, U4 K, m5 P" d
3 The vaccine industry 33* N# S9 n6 Z" L- V+ c# z
4 Vaccine manufacturing 44$ V: n1 I# x/ p# F+ r' e
5 Evolution of adjuvants across the centuries 58 & I/ M4 A2 Y) M6 Vaccine additives and manufacturing residuals in the United States: $ O9 m1 `9 R0 t8 U3 ]1 ^4 \- Zlicensed vaccines 71+ E/ X; s0 g8 G
7 Passive immunization 80 8 e! u+ I1 ?# _7 q. q0 I! x8 General immunization practices 88! G! } E; Q" B5 }) P
SECTION 2: Licensed vaccines# U# I+ [, J2 N: a- m
9 Adenovirus vaccines 1135 h" W+ D& `: {* }6 a0 T6 z. K
10 Anthrax vaccines 127, `8 E* ~. L2 U2 q6 j
11 Cholera vaccines 1415 m- \! F- d$ }2 H8 a- v8 a9 z
12 Diphtheria toxoid 1539 c7 S; L: l" f) h% g
13 Haemophilus influenzae vaccines 167 ) K2 j2 q+ _* V* q1 n14 Hepatitis A vaccines 183 & z: y. S" H9 O7 g0 [15 Hepatitis B vaccines 205: K. |, e' L% ^0 I, c; U
16 Human papillomavirus vaccines 235& G5 k; J2 i/ Z# c
17 Inactivated influenza vaccines 257( Z2 v' \! V) e, O$ M
18 Influenza vaccine-live 2949 `" h+ O/ X) ^6 J$ z4 P, @
19 Japanese encephalitis vaccines 312( A" }3 k$ R" x) A* `3 Q+ \
20 Measles vaccines 352 . W: w) _/ V6 F9 M _21 Meningococcal vaccines 388. n+ n# ?" J' n% [6 A, D4 A
22 Mumps vaccine 419 6 q; I8 v. \4 Q- U23 Pertussis vaccines . 447 0 l8 J2 q5 Y) O) T/ Y# e24 Plague vaccines 493# l" W& B3 ^: q! k2 M
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504 ) l& R% v, B" c$ ]6 @+ P26 Pneumococcal polysaccharide vaccines 542 , p. T# ?! Z$ x% s$ n( }27 Poliovirus vaccine-inactivated . 5738 q1 z8 ], x5 {
28 Poliovirus vaccine-live 598) m7 g3 C- M7 _9 E; i
29 Rabies vaccines .646$ V$ }- x t( u1 t
30 Rotavirus vaccines . 669: s: R% G6 T: x+ a, d9 O
31 Rubella vaccine 688 . m: c0 |7 A4 g8 B32 Smallpox and vaccinia 718" Q% O& o! ~5 X! N: ^
33 Tetanus toxoid 746' Z, `% T$ X* b9 D. Q
34 Tick-borne encephalitis virus vaccines 773% {. o/ o& p4 ~1 G! ^
35 Tuberculosis vaccines 789 : {& d# t/ H; Z% _; F, m- Q36 Typhoid fever vaccines 812( Q, z& s) ^+ g8 I
37 Varicella vaccine 837 % z% M* Y% d- P) [38 Yellow fever vaccine 870 m; o' M; \0 h( _$ G6 c) | s
39 Zoster vaccine 969. K7 ^6 N0 c& p
40 Combination vaccines 981 K F. n! G7 L, }. e% g `SECTION 3: Vaccines in development and new vaccine strategies. X8 @) P" |4 ~# ^" w
41 Biodefense and special pathogen vaccines 10083 ^' m4 H7 \' ~7 @5 F+ k9 [* M" N7 J
42 Therapeutic cancer vaccines 1018* ]1 |# F- [; ^; q
43 Cytomegalovirus vaccines 1032$ A( A* Y" n8 F# t
44 Dengue vaccines 1042. X* y/ c: O+ R: n) z- J G. y
45 Diarrhea caused by bacteria 1052 & y; l7 s' c3 F" h% e: x( [46 Ebola vaccine 1060 ; V' Y( [% A' C4 i0 h47 Epstein-Barr virus vaccines 1068 8 s* Q& M9 Q: T5 o2 V48 Hepatitis C vaccines 1074 ( Z$ i* Z% H+ x3 |! S49 Hepatitis E vaccines 1085 r7 t4 K, `' I1 w4 `3 C
50 Herpes simplex virus vaccines 1090 $ H7 u/ Z1 ?% D: C1 m) T4 B/ j51 Human immunodeficiency virus vaccines 1097, G' q5 x2 c2 v9 U( c
52 Lyme disease vaccines 1122( ^ Q* D. u, ~) D) P* d
53 Malaria vaccines 1133' H5 Q% j, p. R, [6 X- X
54 Noninfectious disease vaccines 11389 @) k4 A$ z/ E$ i
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146 6 T7 {* j- K( G/ U56 Parasitic disease vaccines 1154 . u5 S% S% A0 j2 I* j8 ~. x0 b57 Staphylococcus aureus vaccines 1161 ) ]! S' m! n9 w58 Streptococcus group A vaccines 11698 M* Y' W* s# i0 J% [
59 Streptococcus group B vaccines 1176 ) D9 p# h, N: D! ^( u1 ~60 Technologies for making new vaccines 11824 t1 w: M4 Z: m6 i
61 Alternative vaccine delivery methods 1200 ) y) w6 x8 i; \* M# H' m- [62 The development of gene-based vectors for immunization 1232 5 ?. T9 O; Y2 t, A! I* Y1 ]* Y7 hSECTION 4: Vaccination of special groups : a$ r1 z( R0 T9 h2 n4 T63 Vaccination of immunocompromised hosts 12433 T# F" F1 [* F" q3 t- h
64 Vaccination of human immunodeficiency virus-infected persons 1257 Q m8 Z+ r) S. Y+ D
65 Vaccines for international travel 1270 # E: I& n& y3 {) R66 Vaccines for health care personnel 1290 & _8 f1 I. _* D# mSECTION 5: Public health and regulatory issues - G, F% Z6 i# L67 Immunization in the United States 13100 B i ]# n' w0 }: A6 R
68 Immunization in Europe . 1334+ V) U1 ~; g5 P4 ^2 E( ^) L
69 Immunization in the Asia-Pacific region 1353 7 y& f" h4 Y( y& `: H70 Immunization in developing countries 1369! Y/ t2 I( D! \ ~2 c, L' x# `
71 Community immunity 13959 I" ?7 Y! T c y- i1 u& w& ]
72 Economic analyses of vaccine policies 1413 ; Z; d: n: l9 e3 W, ?73 Regulation and testing of vaccines 1427 ' I; G6 N! K# F) J( Y, {) Y( |74 Regulation of vaccines in Europe 1447 ' a; j6 D4 ]4 B0 Y75 Regulation of vaccines in developing countries 1454 - ?- B( i0 s C) v' E$ L76 Vaccine safety 1464 8 s) h8 y4 N/ \2 C: N77 Legal issues . 1481 9 R: q" l- c7 S6 o; q78 Ethics 15088 X+ w) F3 k V4 u5 Y
@- z0 g/ c: p9 a7 R. O: l2 D6 w# P6 B
S( }1 q- }- V O3 z6 c8 _1 X
7 D0 `4 ^9 S$ lApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice. * N7 a/ k$ U0 Z 9 r( T a6 [+ N$ V# _http://yun.baidu.com/share/link? ... 1&uk=3810996606 , k' x7 U& `' H 1 \& A; f6 E% B9 z4 S) R% HSECTION 1: General aspects of vaccination8 ]1 Z @% ~; Q8 S j7 z
1 A short history of vaccination 14 s8 o( }: _+ b, c! ]7 }
2 Vaccine immunology 144 O/ t9 u" [1 y
3 The vaccine industry 33' q' ?, p/ U) m7 O) s+ ^
4 Vaccine manufacturing 44 : ?/ [% O0 }% H, q. p5 Evolution of adjuvants across the centuries 58# z: B8 U, U4 S m! C9 V; Z0 F3 I9 Z
6 Vaccine additives and manufacturing residuals in the United States: * w7 n1 j) x7 \/ i* [licensed vaccines 71 " ^" W0 ]! q" t( a' i7 Passive immunization 80 2 f+ ^( T$ t0 L9 ~5 h1 ]8 General immunization practices 88% L# u; [8 w) x0 F) k
SECTION 2: Licensed vaccines s! | B# _; F" m: D& J- C& ?
9 Adenovirus vaccines 113. j( [/ O5 H9 a7 Q& {- ]
10 Anthrax vaccines 127 1 |# j/ M% Z( m11 Cholera vaccines 141$ J, ^ [/ Q# o) D. `
12 Diphtheria toxoid 153. ]" k6 ^; t6 ]# n- Q+ g
13 Haemophilus influenzae vaccines 1671 ]0 L- g2 p) v3 [+ B' \. V
14 Hepatitis A vaccines 183 0 p# f% S, ~% s) h' |! o( j15 Hepatitis B vaccines 2054 h1 P1 A- r/ F3 Z) r! b
16 Human papillomavirus vaccines 2358 U& K' v$ A9 U5 {2 o
17 Inactivated influenza vaccines 257 & ^# K; o- {: {9 G3 e18 Influenza vaccine-live 294 ) @/ D) q5 i- b! w% Y9 ]- T19 Japanese encephalitis vaccines 312 : D0 D; v1 }% _20 Measles vaccines 352 - h/ Y( l1 u' f8 M' b21 Meningococcal vaccines 3888 E/ \; m" i& P7 C; Q$ e# K+ {
22 Mumps vaccine 4191 F5 \! i% i" ], a- H
23 Pertussis vaccines . 4476 M! j; A% f3 i) C. S
24 Plague vaccines 4933 p: _3 C1 ] `3 o1 P. w5 m! ~1 _
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504- u9 J* w0 g& \; P8 [
26 Pneumococcal polysaccharide vaccines 542 1 C( Z/ `, z5 V/ o27 Poliovirus vaccine-inactivated . 573, P* ?6 ^! H+ L( p; q# q( S1 X9 S
28 Poliovirus vaccine-live 598. c' g: p$ j- ?! f7 ]8 f
29 Rabies vaccines .646 1 k. \2 M8 l) J5 Z9 b30 Rotavirus vaccines . 669 9 ~% p* w! ~( l31 Rubella vaccine 688* |4 F* A" i4 Q6 i
32 Smallpox and vaccinia 718 9 E/ c: i6 R# R1 X& ~0 x33 Tetanus toxoid 746 " q( S- }) a y' E/ F, m34 Tick-borne encephalitis virus vaccines 773$ D7 J' p* ]/ L! S# n
35 Tuberculosis vaccines 789, k$ E0 Q4 }0 ?# Y/ L g8 \
36 Typhoid fever vaccines 812& |8 G5 \* U, J, o
37 Varicella vaccine 837( a! L4 `" Q% j: h+ K( a
38 Yellow fever vaccine 870; w, ?; i* ?* P" _( y
39 Zoster vaccine 969 ) r( u$ P2 \& `9 d40 Combination vaccines 981 4 O: t. H5 p0 q- C+ E" dSECTION 3: Vaccines in development and new vaccine strategies ( _) v0 z, B1 k1 E- [% u" F. Z+ {41 Biodefense and special pathogen vaccines 10086 g/ J/ _7 o8 o, q6 p* _- W" Y
42 Therapeutic cancer vaccines 1018$ N4 a& M9 w5 B6 \- ~
43 Cytomegalovirus vaccines 10328 r# |4 `5 k, u
44 Dengue vaccines 1042( N) R; Z9 `: u; M! w
45 Diarrhea caused by bacteria 1052 " Z# m* ~ p8 E; c! ^46 Ebola vaccine 1060 - T" \* {5 j- R. l! K% N5 H47 Epstein-Barr virus vaccines 1068& o9 p: F( j3 O. S
48 Hepatitis C vaccines 1074 + K5 V0 Z+ X! I! E/ A5 [7 Q+ c49 Hepatitis E vaccines 1085 % ]9 E, m, P0 h, H& i50 Herpes simplex virus vaccines 1090 K+ _- ], N- d, L. p51 Human immunodeficiency virus vaccines 1097 : k7 A' |& |* [1 e0 t3 B" e+ r52 Lyme disease vaccines 1122 3 U5 o# }2 Q# [( n4 D3 C v1 `53 Malaria vaccines 11335 \6 r: y. v" m( X' O w
54 Noninfectious disease vaccines 1138 - z9 A0 w+ L* |, F) i! j6 h55 Respiratory syncytial virus and parainfluenza virus vaccines 1146# u9 R5 h: j' q- ~9 F; c2 `
56 Parasitic disease vaccines 1154! M+ a# `( J* |
57 Staphylococcus aureus vaccines 1161 2 L- o: m# o8 e- [5 p2 G58 Streptococcus group A vaccines 1169( B+ E" }( S) {7 t
59 Streptococcus group B vaccines 1176# q" t5 r4 Y/ S' h$ b( P
60 Technologies for making new vaccines 11822 g. A9 ^8 o8 }7 e, C6 H+ D) w: B
61 Alternative vaccine delivery methods 12007 P& K6 F- ^ R, n
62 The development of gene-based vectors for immunization 1232 , K6 s9 l" d- h3 fSECTION 4: Vaccination of special groups: i6 O7 h+ o2 a5 R+ R" |7 I
63 Vaccination of immunocompromised hosts 1243/ w2 l3 T+ s9 h X
64 Vaccination of human immunodeficiency virus-infected persons 12572 | v z' P2 B" D, n- u
65 Vaccines for international travel 12702 f- D; B- W6 m. W0 e& n( w6 p
66 Vaccines for health care personnel 1290 1 p9 Z; S$ {+ K% QSECTION 5: Public health and regulatory issues 7 g8 _/ U2 D: Q/ _. ?+ }4 a9 s67 Immunization in the United States 13107 k. x( q6 j% h3 x
68 Immunization in Europe . 1334# L4 c4 ^3 c7 U% V! L
69 Immunization in the Asia-Pacific region 1353' ~; S9 Q) j7 Q6 U; c2 K4 a
70 Immunization in developing countries 1369 5 v, x3 N; c0 T71 Community immunity 1395* k: N% ]0 a/ q! {
72 Economic analyses of vaccine policies 1413 $ B2 q5 _' _# ?73 Regulation and testing of vaccines 14277 a. B4 y$ K1 D2 t
74 Regulation of vaccines in Europe 1447! }$ I$ O& J8 ]/ ~0 |+ z% `
75 Regulation of vaccines in developing countries 1454/ k' ~( M! U' l2 J- W/ V# A
76 Vaccine safety 1464 8 ?6 T* [7 P) _8 ^# w77 Legal issues . 1481 @9 E( D- u& _8 O2 i
78 Ethics 1508 . j/ q7 a) l" A1 t & S' D- G: B7 w9 w 3 D. u) a( I$ q | j8 R# X8 e作者: casarett 时间: 2017-5-2 15:25 Vaccines, 6e, 2012 ! f% F& n# ?/ I- D, h g 2 z4 ~% j! ?: D; `3 `0 W _4 X BHardcover: 1570 pages $ G- ^* A q& Z$ ]* E' m, MPublisher: Saunders; 6 edition (October 30, 2012) 6 B" N) P! t4 u2 ^2 m, x! mLanguage: English. |6 z! v' `7 q; {* v3 [ ISBN-10: 1455700908 6 x1 R& z% H6 hSize: 52.3mb (original pdf)+ J' e9 Z2 {6 R# `7 g, a8 Y
* S5 G- m! N; f6 g 2013 BMA Medical Book Awards Highly Commended in Public Health!; S( \( Z: c) z ~
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice!1 I* {% H7 U& x+ T b
0 v1 @$ a9 h n- B2 ~7 {- }' Z* kGain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.( Q _( T- o1 z( e0 E! T+ p+ T0 Q
Update your knowledge of both existing vaccines and vaccines currently in the research and development stage.3 S8 h# |" D: g
Get complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.) f5 G6 ~) p2 }, L: m* R% h
Analyze the cost-benefit and cost-effectiveness of different vaccine options. % w3 I2 H5 R& D* A' [) PClearly visualize concepts and objective data through an abundance of tables and figures.4 a3 Q6 G# k; G0 t' a d/ @
Perform seamless searches of the complete text online, access all the references, and download all the images at www.expertconsult.com. Q( _- s. N- g
Make optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.* |2 h, X. e' r( J8 i
Stay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.1 R" O& f% h2 V
" d9 t8 C* y& H5 K U0 G; o- D/ HDownload link: http://pan.baidu.com/s/1i5NxwLR ' ~+ X% j- l( C) w4 n, B) y
Code for downloading: dv96 + n! J; H; V1 s& T8 A, _ F: p
